Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574102 | 0.98 | BTK (0.36) | GAAEPHX1HPGDBTKHSD11B1 | |
| SCHEMBL9964560 | 0.96 | BTK (0.37) | GAAEPHX1HPGDBTKHSD11B1 | |
| SCHEMBL4367475 | 0.90 | CHRM2 (0.34) | GAAHPGDBTKHSD11B1CHRM2 | |
| SCHEMBL1783229 | 0.82 | USP2 (0.39) | HSD11B1CHRM2CHRM1CHRM3CTSS | |
| SCHEMBL15021681 | 0.82 | SLC6A4 (0.32) | HSD11B1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL138266 | 0.81 | GAA (0.39) | GAAEPHX1HPGDBTKHSD11B1 | |
| SCHEMBL6262075 | 0.81 | BTK (0.39) | BTKHSD11B1TSHR | |
| SCHEMBL27873293 | 0.80 | CYP2D6 (0.38) | BTKTSHR | |
| SCHEMBL6424027 | 0.80 | PLG (0.38) | CTSSCTSKNFKB1NFKB2RELA | |
| SCHEMBL4552317 | 0.79 | HSD11B1 (0.44) | GAAEPHX1HPGDBTKHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2106396-B1 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ALCON RES LTD (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| EP-2106396-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | AstraZeneca AB (SE) | 2009-10-07 | — | — | EP | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| WO-2008084223-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| US-7138416-B2 | Dipeptidyl peptidase inhibitors; heterocyclic amide and semicarbazide derivatives, e.g., (2-Cyano-1-(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate | TORRENT PHARMACEUTICALS LTD. (IN) | 2006-11-21 | — | — | US | disclosed |
| EP-1583524-A1 | BIS (THIO-HYDRAZIDE AMIDE) COMPOUNDS FOR TREATING MULTI-DRUG RESISTANT CANCER | Synta Pharmaceuticals Corporation (US) | 2005-10-12 | — | — | EP | disclosed |
| CN-1633420-A | Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors | TORRENT PHARMACEUTICALS LTD (IN) | 2005-06-29 | — | — | CN | disclosed |
| EP-1492777-A1 | THIAZOLIDINE-4-CARBONITRILES AND ANALOGUES AND THEIR USE AS DIPEPTIDYL-PEPTIDASE INHIBITORS | Torrent Pharmaceuticals Ltd (IN) | 2005-01-05 | — | — | EP | disclosed |
| EP-1476158-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004064826-A1 | BIS (THIO-HYDRAZIDE AMIDE) COMPOUNDS FOR TREATING MULTI-DRUG RESISTANT CANCER | SYNTA PHARMACEUTICALS CORP. (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040106802-A1 | Novel compounds and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2004-06-03 | — | — | US | disclosed |
| US-20030225102-A1 | Novel compounds and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-12-04 | — | — | US | disclosed |
| WO-2003084940-A1 | THIAZOLIDINE-4-CARBONITRILES AND ANALOGUES AND THEIR USE AS DIPEPTIDYL-PEPTIDAS INHIBITORS | SANKARANARAYANAN ALANGUDI (IN) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003068233-A1 | NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068235-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | GAA 233/4885EPHX1 1023/4885HPGD 303/4885 |
| US-20030225102-A1 | Novel compounds and therapeutic uses thereof | GPR119, SLC5A1, SLC2A4 | GAA 424/4885EPHX1 2934/4885HPGD 1865/4885 |
| US-20040106802-A1 | Novel compounds and therapeutic uses thereof | GPR119, SLC5A1, SLC2A3 | GAA 344/4885EPHX1 1413/4885HPGD 1803/4885 |
| US-20090124596-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | GAA 233/4885EPHX1 1023/4885HPGD 303/4885 |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | PDE4A, PDE4B, PDE5A | GAA 337/4885EPHX1 783/4885HPGD 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.